Clinical Research
Heart Rhythm Disorder
Long QT Syndrome and Pregnancy

https://doi.org/10.1016/j.jacc.2006.09.054Get rights and content
Under an Elsevier user license
open archive

Objectives

This study was designed to investigate the clinical course of women with long QT syndrome (LQTS) throughout their potential childbearing years.

Background

Only limited data exist regarding the risks associated with pregnancy in women with LQTS.

Methods

The risk of experiencing an adverse cardiac event, including syncope, aborted cardiac arrest, and sudden death, during and after pregnancy was analyzed for women who had their first birth from 1980 to 2003 (n = 391). Time-dependent Kaplan-Meier and Cox proportional hazard methods were used to evaluate the risk of cardiac events during different peripartum periods.

Results

Compared with a time period before a woman’s first conception, the pregnancy time was associated with a reduced risk of cardiac events (hazard ratio [HR] 0.28, 95% confidence interval [CI] 0.10 to 0.76, p = 0.01), whereas the 9-month postpartum time had an increased risk (HR 2.7, 95% CI 1.8 to 4.3, p < 0.001). After the 9-month postpartum period, the risk was similar to the period before the first conception (HR 0.91, 95% CI 0.55 to 1.5, p = 0.70). Genotype analysis (n = 153) showed that women with the LQT2 genotype were more likely to experience a cardiac event than women with the LQT1 or LQT3 genotype. The cardiac event risk during the high-risk postpartum period was reduced among women using beta-blocker therapy (HR 0.34, 95% CI 0.14 to 0.84, p = 0.02).

Conclusions

Women with LQTS have a reduced risk for cardiac events during pregnancy, but an increased risk during the 9-month postpartum period, especially among women with the LQT2 genotype. Beta-blockers were associated with a reduction in cardiac events during the high-risk postpartum time period.

Abbreviations and Acronyms

ACA
aborted cardiac arrest
CI
confidence interval
ECG
electrocardiogram
LQTS
long QT syndrome

Cited by (0)

Supported in part by research grants HL-33843 and HL-51618 from the National Institutes of Health, Bethesda, Maryland.